Drug Approval | December 23, 2025
FDA nod to MYQORZO for obstructive hypertrophic cardiomyopathy
The drug is designed to improve functional capacity and reduce symptoms by inhibiting cardiac myosin motor activity
The drug is designed to improve functional capacity and reduce symptoms by inhibiting cardiac myosin motor activity
In 2020, CORXEL acquired the rights to develop and commercialize aficamten in Greater China
The cardiomyopathies market in the 68M is set to grow at a CAGR of 12.1%
Subscribe To Our Newsletter & Stay Updated
